--- title: "PharmaCyte Biotech (PMCB) news: reverse split and offering" url: "https://aibio.space/companies/pharmacyte-biotech/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PMCB reverse split, offering, convertible notes and Nasdaq notice news: PharmaCyte Biotech gets Nasdaq minimum bid price deficiency notice, has until June…" --- PMCB PharmaCyte Biotech, Inc. NASDAQ · United States # PharmaCyte Biotech (PMCB) news PMCB reverse split, offering and convertible notes news Distress · 2025-12-15 ## [PharmaCyte Biotech files NT 10-Q for quarter ended October 31, 2025, citing need for more time](https://aibio.space/news/pharmacyte-biotech-files-nt-10-q-quarter-ended-october-31-2025-citing/) PharmaCyte Biotech will miss the December 15, 2025 deadline for its quarterly report and says it will file within five calendar days. The company's latest annual report says its licensed patents have expired and that the know-how for its core technology sits with a partner, while it has cut program spending during a board review. ## Latest PharmaCyte Biotech news 1. 2025-12-05 Listings [PharmaCyte Biotech gets Nasdaq minimum bid price deficiency notice, has until June 1, 2026](https://aibio.space/news/pharmacyte-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/) Nasdaq told PharmaCyte on December 1, 2025 that its stock had failed the $1.00 minimum bid price over 30 consecutive business days. The company has until June 1, 2026, and any reverse stock split would need shareholder approval. The filings give no share price or cash figure to show how far the company is from compliance. 2. 2025-09-05 Mergers [PharmaCyte Biotech adds $3 million to its stake in TNF Pharmaceuticals](https://aibio.space/news/pharmacyte-biotech-adds-3-million-stake-tnf-pharmaceuticals/) PharmaCyte says the money is meant to support TNF's license of a light-based computing platform for cryptocurrency mining. TNF plans to change its name and ticker. 3. 2025-08-18 Financings [PharmaCyte Biotech agrees $7.0 million convertible preferred private placement](https://aibio.space/news/pharmacyte-biotech-agrees-7-0-million-convertible-preferred-private/) PharmaCyte agreed to sell 7,000 shares of Series C convertible preferred stock, with a $1,000 stated value each, to existing investors for $7.0 million. The preferred converts at $1.00 a share, against $4.00 for the 2023 Series B, and it carries a 7.0% quarterly dividend payable in cash. 4. 2025-07-29 Distress [PharmaCyte Biotech delays annual report for year ended April 30, 2025](https://aibio.space/news/pharmacyte-biotech-delays-annual-report-year-ended-april-30-2025/) The company said it needs more time to prepare and review its financial statements. It plans to file within 15 days of the July 29, 2025 due date. ## PharmaCyte Biotech at a glance - **Ticker**: PMCB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jul 31, 2026**: $17.8 million ### Related companies - [IMMUNOTECH LABORATORIES INC](https://aibio.space/companies/immunotech-laboratories/) OTC: IMMB - [Nutra Pharma](https://aibio.space/companies/nutra-pharma/) OTC: NPHC - [Definium Therapeutics](https://aibio.space/companies/definium-therapeutics/) NASDAQ: DFTX - [Revolution Medicines](https://aibio.space/companies/revolution-medicines/) NASDAQ: RVMD - [Therapeutic Solutions International](https://aibio.space/companies/therapeutic-solutions-international/) OTC: TSOI - [iBio](https://aibio.space/companies/ibio/) NASDAQ: IBIO - [Curanex Pharmaceuticals](https://aibio.space/companies/curanex-pharmaceuticals/) NASDAQ: CURX - [MIRA Pharmaceuticals](https://aibio.space/companies/mira-pharmaceuticals/) NASDAQ: MIRA ### Also on NASDAQ - [Microbot Medical](https://aibio.space/companies/microbot-medical/) MBOT - [Lifevantage](https://aibio.space/companies/lifevantage/) LFVN - [Werewolf Therapeutics](https://aibio.space/companies/werewolf-therapeutics/) HOWL - [Baird Medical Investment Holdings](https://aibio.space/companies/baird-medical-investment/) BDMD - [Alamar Biosciences](https://aibio.space/companies/alamar-biosciences/) ALMR - [Upstream Bio](https://aibio.space/companies/upstream-bio/) UPB ## PharmaCyte Biotech annual financials | Line | FY ended Apr 30, 2026 | FY ended Apr 30, 2025 | |---|---|---| | Revenue | [$0](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | [$0](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | | Research and development | [$391,301](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | [$438,416](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | | Net income (loss) | [-$19.4 million](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | [$30.7 million](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | | Cash from operations | [-$5.2 million](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | [-$3.0 million](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | | Cash and equivalents | [$18.6 million](https://www.sec.gov/Archives/edgar/data/1157075/000168316826007106/) | [$15.2 million](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | | Short-term investments | [$254,010](https://www.sec.gov/Archives/edgar/data/1157075/000168316826007106/) | [$366,316](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/) | Latest balance sheet, Jul 31, 2026 (10-Q): cash and equivalents $17.7 million, plus short-term investments of $99,462, $17.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about PharmaCyte Biotech Did PharmaCyte Biotech do a reverse stock split? Our latest story on this, dated Dec 5, 2025: "PharmaCyte Biotech gets Nasdaq minimum bid price deficiency notice, has until June 1, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pharmacyte-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/). Has PharmaCyte Biotech raised money recently? Our latest story on this, dated Aug 18, 2025: "PharmaCyte Biotech agrees $7.0 million convertible preferred private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pharmacyte-biotech-agrees-7-0-million-convertible-preferred-private/). Has PharmaCyte Biotech sold convertible notes? Our latest story on this, dated Aug 18, 2025: "PharmaCyte Biotech agrees $7.0 million convertible preferred private placement". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pharmacyte-biotech-agrees-7-0-million-convertible-preferred-private/). Has PharmaCyte Biotech received a Nasdaq deficiency notice? Our latest story on this, dated Dec 5, 2025: "PharmaCyte Biotech gets Nasdaq minimum bid price deficiency notice, has until June 1, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/pharmacyte-biotech-gets-nasdaq-minimum-bid-price-deficiency-notice-has/). What is the ticker symbol of PharmaCyte Biotech? PharmaCyte Biotech, Inc. trades under the ticker PMCB on NASDAQ. Where is PharmaCyte Biotech listed? PharmaCyte Biotech, Inc. is listed on NASDAQ. What is the SEC CIK of PharmaCyte Biotech? The SEC Central Index Key (CIK) for PharmaCyte Biotech, Inc. is 1157075. Its filings are on SEC EDGAR. How many shares does PharmaCyte Biotech have outstanding? 10,735,649 shares as of 2026-09-11, per the cover page of its 10-Q filed 2026-09-14. Which country or territory is PharmaCyte Biotech listed under? Our directory records PharmaCyte Biotech, Inc. under United States. What does PharmaCyte Biotech do? Our directory classifies PharmaCyte Biotech, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of PharmaCyte Biotech? The ISIN recorded for PharmaCyte Biotech, Inc. is US71715X2036. Does aibio.space cover PharmaCyte Biotech? aibio.space lists PharmaCyte Biotech, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is PharmaCyte Biotech incorporated? SEC records list its state or country of incorporation as NV. What was PharmaCyte Biotech's revenue last year? $0 for the fiscal year ended Apr 30, 2026, as reported to the SEC. Is PharmaCyte Biotech profitable? PharmaCyte Biotech, Inc. reported a net loss of $19.4 million for the fiscal year ended Apr 30, 2026, and used $5.2 million of cash in operations, per its annual report to the SEC. ## Investor discussion: PharmaCyte Biotech Members talk about PharmaCyte Biotech (PMCB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at PharmaCyte Biotech, newest first. Each line links the filing it comes from. 1. 2026-10-16 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316826007934/pharmacyte_8k.htm) 2. 2026-04-02 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316826002613/pharmacyte_8k.htm) 3. 2026-03-09 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316826001593/pharmacyte_idef14a.htm) 4. 2026-02-27 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316826001363/pharmacyte_ipre14a.htm) 5. 2025-12-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316825009154/pharmacyte_nt.htm) 6. 2025-12-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316825008947/pharmacyte_8k.htm) 7. 2025-09-05 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316825006727/pharmacyte_ex9901.htm) 8. 2025-08-18 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316825006274/pharmacyte_ex9901.htm) 9. 2025-07-29 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316825005492/pharm_nt10k.htm) 10. 2025-02-26 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1157075/000168316825001236/pharmacyte_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PMCB on TradingView](https://www.tradingview.com/symbols/NASDAQ-PMCB/). ## SEC filings and registration - **SEC name**: PharmaCyte Biotech, Inc. - **CIK**: 1157075 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: PMCB (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: April 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 3960 HOWARD HUGHES PARKWAY, LAS VEGAS, NV, 89169 - **Phone**: (917) 595.2850 - **Shares outstanding**: 10,735,649 as of 2026-09-11 (10-Q filed 2026-09-14) - **Former names**: NUVILEX, INC.; EFOODSAFETY COM INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1157075/000168316826007934/pharmacyte_8k.htm) filed 2026-10-16 - [10-Q](https://www.sec.gov/Archives/edgar/data/1157075/000168316826007106/pharmacyte_i10q-073126.htm) filed 2026-09-14 - [10-K](https://www.sec.gov/Archives/edgar/data/1157075/000168316826005836/pharmacyte_i10k-043026.htm) filed 2026-07-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1157075/000168316826002613/pharmacyte_8k.htm) filed 2026-04-02 - [10-Q](https://www.sec.gov/Archives/edgar/data/1157075/000168316826001917/pharmacyte_i10q-013126.htm) filed 2026-03-17 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1157075/000168316826001593/pharmacyte_idef14a.htm) filed 2026-03-09 - [10-Q](https://www.sec.gov/Archives/edgar/data/1157075/000168316825009259/pharmacyte_i10q-103125.htm) filed 2025-12-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1157075/000168316825008947/pharmacyte_8k.htm) filed 2025-12-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157075), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details PharmaCyte Biotech, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PMCB, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: PharmaCyte Biotech, Inc. - **Ticker**: PMCB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: US71715X2036 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PMCB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/pharmacyte-biotech/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "PharmaCyte Biotech (PMCB) news: reverse split and offering", 2026-10-31, https://aibio.space/companies/pharmacyte-biotech/